NCT04143321View on ClinicalTrials.gov

Antiischemic Effects of Empagliflozin in Diabetic Patients With Refractory Angina

PHASE4CompletedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

September 10, 2018

Primary Completion Date

April 15, 2019

Study Completion Date

May 23, 2019

Conditions
Diabetes Mellitus
Interventions
DRUG

Empagliflozin 25 MG

after washout period and EST and SAQ patients gave 25 mg Empagliflozin daily in experimental group

Trial Locations (1)

Unknown

Cardiac rehabilitation research center, Isfahan

All Listed Sponsors
lead

Isfahan University of Medical Sciences

OTHER

NCT04143321 - Antiischemic Effects of Empagliflozin in Diabetic Patients With Refractory Angina | Biotech Hunter | Biotech Hunter